Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3295668 and Osimertinib in EGFR-Mutant NSCLC
NCT05017025Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2022
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of LY3295668 in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2022; status: completed.
02
Drugs
LY3295668
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05017025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017025.